TrialBMC cancer2018

Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators.

Kenichi Inoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.